2 testing labs in Serbia get boost from China
Chinese genomics company BGI Group signed an agreement with the Serbian government on Wednesday to help the European country build two coronavirus testing laboratories, as the pandemic continues to rage across the continent.
The two labs, one located in Belgrade, the Serbian capital, and the other in the southern city of Nis, will be capable of testing a combined 3,000 samples per day once they begin to operate, significantly boosting the country's testing capabilities.
The Belgrade lab will be built at the country's national medical center, which is currently being renovated.
"Thank you for what you have done for the Serbian people at this difficult time," Serbian Prime Minister Ana Brnabic told BGI. "We have received support and help from China in medical supplies, experts, technology and experience from our first day of battling the coronavirus. Without Chinese help, we would not be able to win the battle."
Chinese Ambassador to Serbia Chen Bo said the embassy will continue to provide help so that the two labs can begin operating as soon as possible.
Wang Jian, BGI's founder and chairman, said testing is crucial for early detection and control of the coronavirus. It can effectively prevent delays of medical treatment and reduce public panic.
2026-10-02
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
China’s 15th Five-Year Plan Sets New Priorities for Pharmaceutical Innovation and Supply Chains
-
Evonik Expands Slovakian Fermas Site with €80 Million Investment to Boost Pharmaceutical CDMO Capacity
-
India's PV Community Comes Together at the 6th Edition Drug Safety Symposium 2026 – India Chapter to Shape the Future of Patient Safety
-
The project of fine chemicals with 4000 t/a Tebuconazole and Diflufenican is to be built
-
Pharmaconex 2022
-
CPHI Korea 2022
-
Shandong Pharmaceutical Companies Grab Over $1 Billion of Antithrombotic Drugs for The First Imitation, Original Research Drugs Soared 5527%
-
ECHEMI International Trade Business School Bangladesh Pharmaceutical Summary
-
Industrialization Progress of genetically modified pharmaceutical products
-
2022 Top 50 Global Pharmaceutical Companies Released! Pfizer Returns to NO.1, Kexing Counterattack First on the List
Recommend Reading
-
New Titanium Dioxide Alternative Moves Closer to Market
-
Rising API Costs Threaten Drug Prices
-
Lilly Bets Bigger on China
-
India Issues Final Anti-Dumping Ruling on Chinese TDQ, with Duties Up to US$549 per Ton
-
“Amputation or Strategic Retreat?”: Shell’s Six-Year Chemical Losses and the Quiet Unwinding of an Empire
-
China's Propylene Oxide Market Prices Show a High-Level Correction (2.2-2.6)
-
This Week's Epichlorohydrin Market Prices Decline in China (2.2-2.6)
-
Supply and Demand Boost Formic Acid Prices Gradually in China
-
Supply and Demand Weakness, Flexible Fluctuations in the Melamine Market
-
Ample Supply, Toluene Market Declines in China